Evotec SE (ETR:EVT – Get Free Report) traded up 4.3% on Monday . The stock traded as high as €6.33 ($7.03) and last traded at €6.30 ($6.99). 801,059 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 1,360,000 shares. The stock had previously closed at €6.04 ($6.71).
Evotec Price Performance
The company has a debt-to-equity ratio of 46.81, a quick ratio of 2.97 and a current ratio of 1.83. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -6.56, a price-to-earnings-growth ratio of 0.98 and a beta of 1.05. The business’s 50 day simple moving average is €7.20 and its 200-day simple moving average is €9.69.
Evotec Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
- Five stocks we like better than Evotec
- What is a Special Dividend?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
